NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES
 
Reference is made to the announcement made by NorDiag ASA (the "Company") 18 November 2011. The subscription period in connection with the Company's rights issue expired at 17:30 (CET) on 2 December 2011.
 
A preliminary count indicates that NorDiag has received subscriptions for 115,827,720 new shares at the end of the subscription period. The rights issue is underwritten for NOK 15 million worth of shares.
 
The final allocation of the shares offered in the rights issue is expected to take place on 8 December 2011, in accordance with the allocation criteria set out in the prospectus dated 17 November 2011. The final result of the rights issue is expected to be published on 8 December 2011, and letters regarding allocation of new shares and the corresponding subscription amount to be paid by each subscriber, is expected to be distributed on the same day.
 
The payment date for the new shares is 14 December 2011.
 
For further information, please contact:
CEO Mårten Wigstøl,   Phone: +47 911 65775
CFO Tone Kvåle,   Phone: +47 915 19576
 
About NorDiag:
NorDiag is a biotechnology company developing, manufacturing and marketing automated solutions (instruments and reagents) for sample preparation of DNA from difficult biological samples. DNA diagnostics give more rapid and precise answers, and are the fastest growing field within diagnostics. The Company's sample preparation solutions are today used in connection with STI, tuberculosis, MRSA, respiratory pathogens and viruses on instruments for large and small laboratories. NorDiag was founded in 2003 and has its headquarters in Oslo, Norway. The Company has offices and laboratories in Stockholm, Sweden and in Atlanta (GA), USA. The group has today 31.6 man-labour years. NorDiag is listed on the Oslo Stock Exchange with ticker NORD.

 
Read the notice in Norwegian here.

For further information - www.nordiag.com .
 
This information is subject of the disclosure requirements acc. to §5-12 vphl (Norwegian Securities Trading Act)